Destina Chemistry
Enabling the routine use of miRNAs in drug development and clinical diagnostics
miRNA detection using immunoassay workflows & platforms
Single-Platform Multi-Omic (miRNA + Protein)
Solves PCR limitiations through detection of all isomiRs
PLATFORM AGNOSTIC: VALIDATED ON MULTIPLE PLATFORMS
Expands utility & menu of existing platforms
PROVIDES NEW OPPORTUNITIES FOR IMPACTFUL ASSAYS
MicroRNAs are powerful early disease biomarkers, but their adoption in drug development and diagnostics settings has been limited by instability, isomiR detection complexity with PCR-based methods, and inconsistent results. Our patented Chemistry overcomes these barriers, unleashing the power of miRNA biomarkers.
First Implementation Case: RUO LiverAce™ Kits
Assays for early hepatotoxicity testing in drug development and clinical trials.
miR-122 & CK-18 — Recognized by FDA as DILI biomarkers
For Research Use Only
Not for use in diagnostic procedures
Data-Driven Insights
Overcoming the challenges of miRNA detection of PCR.
RNA Stabilization
Click for Research Details →
isomiR Detection Capability
Click for Research Details →
Early Detection
Click for Research Details →
Transform Your Analytical Capabilities
"Connect with our specialists to purchase kits or to explore technology licensing and custom assays for your miRNA/proteins of interest"
Get in Touch